Exagen’s autoimmune bet: Can a fast‑growing niche diagnostics player turn scale into durability?
On Exagen’s Q1 2026 earnings call, CEO John Aballi pointed to record first‑quarter revenue and share gains in a $2.2 billion autoimmune testing market where the…